Bei Jing Shang Bao·2025-12-18 11:56Core Viewpoint - Increasing number of pharmaceutical companies are investing in funds to enhance innovation and gain access to emerging technologies and startups, reflecting a strategic shift in the industry towards capital operations for additional revenue and risk diversification [1][7][10] Group 1: Recent Fund Investments - On December 17, 2023, Furuya Medical and Boteng Co. announced their plans to invest in funds, with Furuya Medical committing up to 93 million yuan in a private equity fund focused on high-tech innovation [4] - Boteng Co. plans to acquire a portion of the Yifeng Yunding Fund for 1 yuan, with a commitment to contribute 20 million yuan, targeting investments in the healthcare sector [4][9] Group 2: Industry Trends - Multiple pharmaceutical companies, including Huilong Pharmaceutical, Yingke Medical, and Pianzaihuang, have made similar fund investments this year, indicating a growing trend in the industry [6] - Huilong Pharmaceutical's recent investment focuses on late-stage clinical projects with clear commercial potential, while Pianzaihuang has engaged in several fund investments, emphasizing a strategic approach to enhance core competitiveness [6][10] Group 3: Strategic Benefits - Investing in funds allows pharmaceutical companies to access cutting-edge technologies and market dynamics, potentially leading to future business expansions and technology introductions [5][8] - The strategy also facilitates partnerships within the industry, enhancing resource sharing and competitive advantages [5][8] Group 4: Investment Focus - The funds being invested in primarily target the biopharmaceutical sector, with a focus on innovative drugs, high-end medical devices, and health technology [9][10] - Furuya Medical's targeted fund emphasizes international cooperation and strategic emerging industries, with at least 50% of investments directed towards biopharmaceuticals and health technology [9][10]